Peripheral blood mononuclear cell therapy - Beike Biotech

Drug Profile

Peripheral blood mononuclear cell therapy - Beike Biotech

Alternative Names: PBSC

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Beike Biotechnology
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Granulocyte colony-stimulating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic foot

Most Recent Events

  • 03 Nov 2009 Phase-I/II clinical trials in Diabetic foot in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top